S-095029

N/A

Report date: 2026/02/14 20:00:22

Base Information

Drug NameS-095029
Drug Alias NameS-095029
ClassificationBiologics
Mechanisms of ActionNK cell lectin-like receptor subfamily C member 1 antagonistsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsNK cell lectin-like receptor subfamily C antagonists +[4] 
TargetsNK cell lectin-like receptor subfamily C member 1NK cell lectin-like receptor subfamily C
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInstitut De Recherches Internationales Servier
China Registration ClassN/A

Develop Information

Active CompaniesAdir SarlServier Bio-Innovation LLCInstitut De Recherches Internationales Servier +[5] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A